Stumbling Block for Adolor (The Motley Fool via Yahoo! News)
The U.S. Food and Drug Administration (FDA) has always had a reputation for its conservative approach to drug approvals, because it receives much more flack whenever a drug it has approved shows unexpected side effects than it does for delaying potentially helpful new therapies. Yesterday, shares of drug developer Adolor (Nasdaq: ADLR - News) were smacked for the second time in two months after

FDA plans tougher review of devices (Boston Globe)
WASHINGTON -- The Food and Drug Administration yesterday outlined a plan for tougher monitoring of the safety of medical devices once the products are on the market. It comes just after Democrats , who promise more aggressive oversight of the FDA, wrested control from Republicans in the House of Representatives and Senate.